Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Comorbidities Drive Excess Mortality After Breast Cancer Diagnosis in Childhood Cancer Survivors

Key clinical point: Childhood cancer survivors have an elevated risk of death after a breast cancer diagnosis mainly because of comorbidities related to previous therapies.

Major finding: Compared with peers with breast cancer as their first cancer, childhood cancer survivors with breast cancer had elevated risks of dying from breast cancer (hazard ratio, 1.3), from any cause (HR, 2.4), and especially from other health-related causes (HR, 5.5).

Study details: A retrospective cohort study of 274 female breast cancer patients who were survivors of childhood cancers (Childhood Cancer Survivor Study) and 1,095 matched female breast cancer patients with de novo disease (Surveillance, Epidemiology, and End Results database).

Disclosures: Dr. Moskowitz reported that she has a consulting or advisory role with Bioclinica. The study was supported by the National Cancer Institute, a Memorial Sloan Kettering Cancer Center Core grant, the Meg Berté Owen Foundation, and the American Lebanese Syrian Associated Charities.

Citation:

Moskowitz CS et al. J Clin Oncol. 2019 Jul 1. doi: 10.1200/JCO.18.02219.